参考文献/References:
[1] 谭业颖,田嘉禾,张锦明,等.18F-FLT PET显像诊断肺单发结节及评价细胞增殖的价值.中华核医学杂志,2007,48(2):65.
[2] Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymitine and 18F-fluorodeoxyglueosepositron emission tomography. Chest, 2006, 129(2):393-401.
[3] van Waarde A, Cobben DC, Suunneijer A J, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med, 2004, 45(4):695-700.
[4] Yavuamuto Y, Nishiyama Y, Ishikawa S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 2007, 34(10):1610-1616.
[5] Buck AK, Halter G, Schimneisler H, et al. Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG. J Nucl Med, 2003, 44(9):1426-14317.
[6] Mankoff DA, Shields AF, Krohu KA. PET imaging of cellular proliferation. Radiol Clin North Am, 2005, 43(1):153-167.
[7] 柳曦,周乃康,张锦明,等.18F-FLT摄取与肺癌细胞增殖的相关性.癌症,2006,25(12):1512-1516.
[8] Bading JR, Shiehts AF. Imaging of cell proliteration:status and prospects. J Nucl Med, 2008, 49(Suppl 2):64S-80S.
[9] Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3’-deoxy-3’-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med, 2004, 45(10):1754-1758.
[10] Barthcl H, Cleij MC, Collingridge DR, et al. 3’-deoxy-3’-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res, 2003, 63(13):3791-3798.
[11] Shields AF, Mankoff DA, Link JN, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med, 1998, 39(10):1757-1762.
[12] Reinhardt M J, Kubota K, Yamada S, et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy:a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med, 1997, 38(2):280-287.
[13] Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med, 2002, 43(9):1210-1217.
[14] 柳曦,周乃康,张锦明,等.18F-FLT在肺癌模型小鼠体内的生物分布及PET显像研究.解放军医学杂志,2006,31(10):960-962.
[15] 魏荣卿,Machulla HJ,刘晓宁.检测肿瘤增殖的显像剂18F-FLT.中华核医学杂志,2005,25(1):59-61.
[16] Been LB, Suumeijer AJ, Cobben DC, et al.[18F] FLT-PET in oncology:current status and opportunities. Eur J Nucl Med Mol Imaging, 2004, 31(12):1659-1672.
[17] Dittmann H, Dohmen BM, Kehlbaeh R, et al. Early changes in[18F] FLT uptake after chemotherapy:an experimental study. Eur J Nucl Med Mol Imaging, 2002, 29(11):1462-1469.
[18] Apisanthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3’-deoxy-3’-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006; 12(15):4590-4597.
[19] Chao KS. Functional imaging for early prediction of response to chemoradiotherapy:3’-deoxy-3’-18F-fluorothymidine position emission tomography-a clinical application model of esophageal cancer. Semin Oncol, 2006, 33(6 Suppl 11):S59-S63.
[20] 柳曦,.PET示踪剂18F-FLT在肿瘤学中的研究进展.第三军医大学学报,2006,28(12):1351-1353.
[21] 张锦明,朱虹,姚树林,等.18F-FDG和18F-FLT早期检测肺癌放疗、化疗疗效的实验研究.中国医学影像技术研究会第六次全圉会员代表大会暨第二十二次学术大会论文汇编,北京.2008:238-239.
[22] Sohn HJ, Yang YJ, Ryu JS, et al.[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res, 2008, 14(22):7423-7429.
[23] Dohmen BM, Shiehts AF, Dittmann H, et al. Use of[18F]FLT for breast cancer imaging. J Nucl Med, 2001, 41(Suppl):29.
[24] Pio BS, Park CK, Pietras R, et al. Usefulness of 3’-[F-18]fluoro-3’-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 2006, 8(1):36-42.
[25] Direcks WG, van Gelder M, Lammertsma AA, et al. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo. Cancer Biol Ther, 2008, 7(4):532-537.
[26] Direcks WG, Berndsen SC, Prnost N, et al.[18F]FDG and[18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy:an in vitro study. Br J Cancer, 2008, 99(3):481-487.
[27] Pan MH, Huang SC, Liao YP, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol, 2008, 10(6):325-334.
[28] Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to nenadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol, 2009, 19(6):1347-1357.
[29] Dittmann H, Jusufoska A, Dohmen BM, et al. 3’-Deoxy-3’-[18F] fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliteration after doxorubicin and docetaxel treatment. Nucl Med Biol, 2009, 36(2):163-169.
[30] Buck AK, Pitterle K, Schirrmeister H, el al.[18F] FLT positron emission tomography for imaging non-Hodgkin’s lymphoma and assessment of proliferative activity. J Nucl Med, 2003, 44(2):188-189.
[31] Buck AK, Kratochwil C, Glatting G, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue[18F]FLT. Eur J Nucl Med Mol Imaging, 2007, 34(11):1775-1182.
[32] Herrmann K, Wieder HA, Buek AK, et al. Early response assessment using 3’-deoxy-3’[18F]fluorothymidine-positrnn emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Cancer Res, 2007, 13(12):3552-3558.
[33] Graf N, Herrmann K, den Hollander J, et al. Imaging proliferation to monitor early response of iymphoma to cytotoxic treatment. Mol Imaging Biol, 2008, 10(6):349-355.
[34] Murayama C, Harada N, Kakiuehi T, et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med, 2009, 50(2):290-295.
[35] Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with 3-[F-18]-fluoro-3-deoxythymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging, 2007, 34(6):878-883.
[36] Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med, 2004, 45(3):519-525.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[4]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[5]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[6]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[7]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[8]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[11]刘春利,李毅红.18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值[J].国际放射医学核医学杂志,2013,37(2):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
LIU Chun-li,LI Yi-hong.The value of 18F-FDG PET/CT in diagnosing brain metastases from unknown primary tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
[12]王胜军,杨卫东,赵小虎,等.18F-FDG PET/CT诊断多发癌的价值[J].国际放射医学核医学杂志,2013,37(2):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
WANG Sheng-jun,YANG Wei-dong,ZHAO Xiao-hu,et al.Value of 18F-FDG PET/CT in the diagnosis of multiple primary malignant neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
[13]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
[14]江茂情,吴华.18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用[J].国际放射医学核医学杂志,2012,36(6):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
JIANG Mao-qing,WU Hua.18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
[15]江茂情,吴华.18F-FDG和18F-FLTPET对肿瘤放化疗疗效评价的实验研究[J].国际放射医学核医学杂志,2011,35(3):146.[doi:10.3760/cma.j.issn.1673-4114.2011.03.004]
JIANG Mao-qing,WU Hua.The experimental study on 18F-FDG and 18F-FLT PET in assessing the outcome of cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):146.[doi:10.3760/cma.j.issn.1673-4114.2011.03.004]
[16]周敏,魏秋霞,林俊杰,等.良恶性肿瘤18F-FDG符合线路显像的临床价值[J].国际放射医学核医学杂志,2011,35(5):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
ZHOU Min,WEI Qiu-xia,LIN Jun-jie,et al.18F-FDG coincidence imaging for the detection of benign and malignant neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
[17]张慧玮,赵军.18F-FDG代谢显像相关分子机制的研究进展[J].国际放射医学核医学杂志,2011,35(1):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
ZHANG Hui-wei,ZHAO Jun.Progress of molecular mechanism of 18F-FDG metabolism imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
[18]李亚军,张慧娟.放射性核素标记胆碱与18F-FDG PET肿瘤显像的对比研究[J].国际放射医学核医学杂志,2010,34(6):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
LI Ya-jun,ZHANG Hui-juan.Comparison choline with 18F-FDG PET in various tumors imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
[19]司宏伟,徐慧琴,岳峤,等.肿瘤组织乏氧与葡萄糖代谢[J].国际放射医学核医学杂志,2009,33(4):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
SI Hong-wei,XU Hui-qin,YUE Qiao,et al.Hypoxia and glycometabolism in cancer tissue[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
[20]陈香,赵晋华.PET及PET-CT在监测肿瘤治疗效果中的价值[J].国际放射医学核医学杂志,2007,31(6):354.
CHEN Xiang,ZHAO Jin-hua.Value of PET and PET-CT for monitoring tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):354.